logo

For the Inventor, By the Inventor

Brookline, MA, United States of America

Alfred L Goldberg

USPTO Granted Patents = 11

Average Co-Inventor Count = 1.7

ph-index = 4

Forward Citations = 149(Granted Patents)


Location History:

  • Brookline, MA (US) (1983 - 2018)
  • Boston, MA (US) (2018)

Company Filing History:

goldMedal11 out of 2,968 
 
Harvard College
 patents
silverMedal1 out of 130 
 
Biogen, Incorporated
 patents
where one patent can have more than one assignee

Years Active: 1983-2018

Loading Chart...
11 patents (USPTO):Explore Patents
1. 10036016 - Methods for inducing glucose uptake (2018-07-31),
2. 9925251 - [object Object] (2018-03-27),
3. 6660268 - Proteasome regulation of NF-KB activity (2003-12-09),
4. 6027932 - Methods of improving viability of cells at low temperature (2000-02-22),
5. 5972636 - ATP-dependent protease and use of inhibitors for same in the treatment (1999-10-26),
6. 5786329 - ATP-dependent protease and use of inhibitors for same in the treatment (1998-07-28),
7. 5565351 - ATP-dependent protease and use of inhibitors for same in the treatment (1996-10-15),
8. 5340736 - ATP-dependent protease and use of inhibitors for same in the treatment (1994-08-23),
9. 4980160 - Combinations of tumor necrosis factors and anti-inflammatory agents and (1990-12-25),
10. 4758512 - Hosts and methods for producing recombinant products in high yields (1988-07-19),
11. 4390629 - Polypeptide degrading enzymes (1983-06-28),

Title: Alfred L. Goldberg: Innovator in Glucose Uptake and Protease Complex Research

Introduction

Alfred L. Goldberg, an esteemed inventor located in Brookline, MA, has made significant contributions to the fields of biochemistry and molecular biology. With an impressive portfolio of 11 patents, his work continues to impact the understanding of glucose metabolism and tuberculosis treatment.

Latest Patents

Goldberg's latest patents include innovative methods for inducing glucose uptake in muscle cells. One method focuses on inhibiting the Trim32 protein, while another emphasizes increasing the abundance of plakoglobin protein within the cells. Additionally, he has developed technology concerning treatments for tuberculosis that target the ClpP1P2 protease complex, including ClpC1. His research further extends to developing assays and screens for modulators of this protease complex.

Career Highlights

Throughout his career, Alfred L. Goldberg has been affiliated with prominent institutions such as Harvard College and Biogen, Incorporated. His work has not only contributed to scientific knowledge but has also paved the way for potential therapeutic advancements.

Collaborations

Goldberg has collaborated with notable peers in his field, including Olga Kandror and Vito J. Palombella. These collaborations have enriched his research and fostered innovation through shared expertise and insights.

Conclusion

In summary, Alfred L. Goldberg’s extensive patent portfolio and collaborations highlight his dedication to advancing scientific understanding and treatment methodologies. His work establishes him as a key figure in innovation, particularly in the realms of glucose uptake and tuberculosis treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…